![]() |
Open for inclusion |
A Phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype – The P[R]EBEN studyCancer type: Lymphoma Phase: I/II Principal Investigator: dAmore Francesco Country: DK Keywords: pixantrone aggressive lymphoma, Denmark, Aarhus Status: Open for inclusion |